Drawing for SURGERX

USPTO serial 97302599

SURGERX

Reviewed by CopyMark Law Group

Status 733Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
VAUSS, JERAMEY WALLACE
Law office
TMEG LAW OFFICE 105

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 733: Status 733 means the fourth six-month extension was granted. Only one extension typically remains before you must file a Statement of Use or risk abandonment.

Need help with SURGERX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sara M. Bauer

Sara M. Bauer Womble Bond Dickinson (US) LLP470 Atlantic Avenue, Suite 600Independence WharfBoston, MA 02110

Goods and services

ClassDescriptionStatusFirst use
005Hydrogel for medical purposes; Natural biomaterial for delivery of immunotherapy; pharmaceutical preparations used to modulate an immune response; pharmaceutical preparations for the treatment of cancer and for enhancing immune response to tumors; therapeutic agents for impacting immune-stimulating cells; therapeutic agents for impacting immune-suppressive cells; pharmaceutical preparations for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; biological preparations for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; drug delivery agents in the form of injections for medical purposes for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, biomaterials to extend the release of immunotherapy treatments at the site of tumor resection; Natural intraoperative biomaterial for delivery of immunotherapyACTIVEFeb 4, 2026
010Artificial biomaterial for delivery of immunotherapy; Artificial intraoperative biomaterial for delivery of immunotherapyACTIVEFeb 4, 2026

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 8, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 7, 2026EX4GSOU EXTENSION 4 GRANTED—
Aug 7, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 7, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 21, 2026EXT4SOU EXTENSION 4 FILED—
Apr 21, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 1, 2026IUAFUSE AMENDMENT FILED—
Mar 1, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 16, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 15, 2025EX3GSOU EXTENSION 3 GRANTED—
Oct 15, 2025EXT3SOU EXTENSION 3 FILED—
Oct 15, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 16, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 16, 2025EX2GSOU EXTENSION 2 GRANTED—
Apr 16, 2025EXT2SOU EXTENSION 2 FILED—
Apr 16, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 8, 2024EX1GSOU EXTENSION 1 GRANTED—
Oct 8, 2024EXT1SOU EXTENSION 1 FILED—
Oct 8, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 23, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 4, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 27, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 7, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 7, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 24, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 24, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Jan 24, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 24, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 24, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 8, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 7, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 7, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 27, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 27, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 27, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 27, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 27, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 25, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Aug 25, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jun 8, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 8, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 8, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 9, 2023RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Nov 4, 2022GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 4, 2022GNSLLETTER OF SUSPENSION E-MAILED—
Nov 4, 2022CNSLSUSPENSION LETTER WRITTEN—
Nov 4, 2022GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 4, 2022GNSLLETTER OF SUSPENSION E-MAILED—
Nov 4, 2022CNSLSUSPENSION LETTER WRITTEN—
Oct 21, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 21, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 21, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 21, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2022DOCKASSIGNED TO EXAMINER—
Mar 14, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 12, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance